Categories
Business

In-Depth Peek at INMED Pharmaceutic com NPV (OTCMKTS:IMLFF)

INMED PHARMACEUTIC COM NPV (OTCMKTS:IMLFF) is an emerging Canadian medical marijuana play that’s been seeing increased interest in recent days. The ostensible catalyst is the company’s announcement of progress on its R&D program in the use of cannabinoids for the treatment of chronic obstructive pulmonary disease (COPD).

The stock has been tracking in a sideways range for the past six weeks after exploding higher by more than 150% in September and October on a major increase in trading volume (120% over the long run average in daily transactions). The move breaks the stock out of its longer-term bearish trend and points technical indicators higher, so we thought it was a good time to take a closer look at this one.

INMED PHARMACEUTIC COM NPV (OTCMKTS:IMLFF) is a pre-clinical stage biopharmaceutical company that engages in the research and development of novel and cannabinoid-based therapies in Canada.

The company’s products under pre-clinical development stage include INM-750 for the treatment of epidermolysis bullosa; and INM-085 for the treatment of glaucoma. It is also developing various drugs for diseases, such as ocular, pain and inflammation, dermatology, central nervous system, metabolic, and respiratory.

The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada.

As far as the balance sheet, IMLFF has a market cap of $9.3M, with a decent store ($124.28k) of cash on the books, total assets above $1.2M, and virtually no accumulated debt. That’s a much healthier status than most of its peers.

Catalysts Abound

As noted above, InMed initiated its COPD program last year and has been using its bioinformatics analysis tool to identify the targets and potential active compounds that can be useful for the treatment of COPD. Subsequently, with in vitro assays using human lung fibroblasts (HFL-1 cell line), InMed has demonstrated that certain cannabinoid compounds are capable of affecting a specific protein in the biochemical pathway relevant to healing and fibrosis in the lung.

That represents a major step toward getting a foothold into a huge growth market that most folks know very little about. It’s worth exploring. The global COPD market is estimated to currently be worth $11.3 billion, and is forecast to reach a value of $15.6 billion by 2019 according to GBI Research.

Dr. Sazzad Hossain, Chief Scientific Officer of InMed, noted, “Taking into consideration the impact of this specific protein’s role in lung tissue remodeling and fibrosis, these preliminary data are important and promising for developing cannabinoid-based therapies for COPD.” It is well known that cannabinoids exhibit bronchodilatory, immunosuppressive, and anti-inflammatory properties and thus cannabinoid-based therapies may offer safer and more effective treatment options for COPD.

“We continue to make significant scientific progress that further validates InMed’s proprietary bioinformatics analysis tool as a cost-effective way to identify drug-disease targets and expedite their validation in pre-clinical models,” added Dr. Ado Muhammed, Chief Medical Officer of InMed.  “In addition to our primary drug development programs in Epidermolysis Bullosa and Glaucoma, we are pleased to continue to expand the role of cannabinoids in other disease areas.”
Oh Canada

In addition, IMLFF has another distinct advantage: Canada is the place to be right now when it comes to pot. According to a recent Bloomberg article, Canada’s push to legalize marijuana could be a “game changer” for the recreational pot industry with the potential to reach C$6 billion ($4.5 billion) in sales by 2021. A massive black market for marijuana exists in Canada that Canaccord Genuity analysts believe, if brought into legal channels, might bring about sales of 400K kg, or nearly 900K lbs, of cannabis in year one.

If legalization occurs along expected timelines, there will be about 3.8 million legal recreational users of marijuana across Canada by 2021, according to the note. Demand for medical cannabis is growing at a significant pace and by 2021, combined annual demand for medical and recreational cannabis will be about 575,000 kilograms, the Canaccord report said.

While nothing is certain in the wild Canadian cannabis craze, we can rely on one basic idea: this is a good place to buy your lotto tickets. Our research into recent trends and upcoming catalysts suggests IMLFF is an interesting stock to keep on the radar.

Here is the Business Case for the Investment:

InMed’s management believes that it could get INM-750 through trials and approved for less than $40 million.  That would be the advantage of having an all-natural treatment which is much more cost effective.  As an orphan-drug is also isn’t hard to get patients to enroll for trials which shortens the time window and eases cash burn.

Currently, there are no approved treatments for EB. InMed’s lead product, INM-.‐750 targets cannabinoid receptors in the skin to deliver symptomatic relief for all 5 hallmarks of the disease:

  • accelerated wound healing
  • pain reduction
  • anti-itch properties
  • antimicrobial activity
  • anti-inflammation

AND may even re-establish the epidermal/dermal junction by upregulation of specific keratins in the skin, essentially reversing the disease.

 

Market Validation $$ of InMed research:

A Biotech studying EB called Scioderm was acquired by Amicus for $847M!

  • Scioderm’s sole clinical asset is ZorblisaTM, a Ph3 product in development for EB
  • Scioderm was acquired by Amicus in Sept ‘15 for US $847M.

The Acquisition was based on results from just 42 patients in a Phase 2b study

  • JP Morgan and Cowen research reports estimate peak sales for ZorblisaTM in EB of $900M – $1.2Billion

So InMed Investors can look forward to huge potential investment win And That’s only one of their Drugs.

Other notable stocks in the biotechnology sector to keep an eye are  Mast Therapeutics Inc (NYSEMKT:MSTX), Novavax, Inc.(NASDAQ:NVAX), Peregrine Pharmaceuticals (NASDAQ:PPHM) andOpexa Therapeutics Inc (NASDAQ:OPXA).

 

 

Categories
Business

Terra Tech Corp (OTCMKTS:TRTC) Provides Company and Industry Update

Terra Tech Corp (OTCMKTS:TRTC) has announced that its CEO Derek Peterson was recently interviewed by SmallCapVoice.com, in which he provided an industry and company update. The audio interview has been made available on the company website. In his interview, Mr. Peterson discussed the recent election, cabinet appointments and the outlook of the company. He also discussed the state of the cannabis industry and the legalization in Nevada and California.

Separately, the CEO voiced his belief that the incoming government would respect the rights of states to make autonomous decisions, thereby allowing the cannabis industry to thrive. He also pointed out that the president-elect has already claimed that cannabis regulations would be decided on a state-by-state basis, which also indicate that he is aware of the economic benefits the industry has to offer.

Mr. Peterson also stated that a significant amount of tax revenues are being generated, through the industry, since approximately half of the US states have legalized marijuana for medical or recreational use. He also dismissed the beliefs that the new administration might not favor state-level legalization, by claiming that the overwhelming response in favor of marijuana legalization, observed on election day, would make lawmakers reluctant to stifle the new industry.

Terra Tech has also been gaining a lot of attention from analysts of the cannabis industry, which can be seen by the fact that its CEO was recently appointed to the Q&A panel of the Arcview Investor Forum, held in Las Vegas. The event was held on November 15, 2016 and is aimed at helping new and upcoming cannabis companies, network and collaborate with investors. The Arcview Angel Network, which organizes the forum, has over 550 accredited investors and has so far helped over 133 cannabis companies, in raising funds. The event is held on a quarterly basis and is comprised of in-person pitch, which are analyzed by the panel. Mr. Peterson’s inclusion hints that TRTC is being widely viewed as a successful company in the industry.

Terra Tech Corp (OTCMKTS:TRTC) closed at a share price of $0.292, at the end of the November 23 trading session, 10% higher than the day before.

Categories
Business

OrganiGram Holdings Inc (OTCMKTS:OGRMF) To Partner With The Trailer Park Boys

OrganiGram Holdings Inc (OTCMKTS:OGRMF) has announced that it has been chosen by the Trailer Park Boys, based in Nova Scotia, as their exclusive Canadian cannabis producer, brand developer and business partner. As per the agreement, the company would be working closely with the management at TPB Productions Ltd, so as to develop a competitive product portfolio, as well as branding and packaging for the users of recreational marijuana. Moreover, Oranigram would serve as the exclusive distributor for the products.

Ray Gracewood, the CCO of OGRMF, stated that the relationship would solidify their strategic building blocks, as they continue to plan for the legalization of recreational cannabis, in Canada. He also revealed that TPB had a vision to develop a national brand and it was exciting to know that OGRMF could assist them. Mr. Gracewood also reaffirmed that OgraniGram would continue to supply world class cannabis, to its patient base. He clarified that the said partnership was aimed at utilizing opportunities that would be available, once recreational cannabis has been legalized.

It should be noted here that TPB was represented by the Sonic Entertainment Group, in this transaction. Louis Thomas, the president of Sonic Entertainment, stated that they were carefully monitoring the situation in Canada, to understand how best they could enter the market. He further claimed that the timing of this partnership and the selection of OrganiGram was decided after meeting with the executive team of OGRMF. The agreement between the two entities would be valid for a period of 5-years.

The announcement comes just a week after OgraniGram announced its financial results for the 3Q2016 and also provided an operational update. In the update, the company stated that it has started construction of its fully funded expansion plans, announced earlier, which are due to be completed by fall 2017. Once complete, the expanded facility would be able to deliver a production capacity of an estimated 17,235 kg of flower per year, which translates to over $100 million in annual sales.

OrganiGram Holdings Inc (OTCMKTS:OGRMF) had a trade volume of 387,421 and gained 26.07%, during the November 23 trading session, to close at $2.47 per share.

Categories
Marijuana MMJ

Medical Marijuana Inc (OTCMKTS:MJNA)’s Mexican Arm Featured In Newsweek

Medical Marijuana Inc (OTCMKTS:MJNA) has stated that its Mexican subsidiary, HempMeds has been featured in Newsweek. The company stated that the coverage focused on Real Scientific Hemp Oil-X, a non-psychoactive, THC free hemp based CBD product from HempMeds. It should be noted here that RSHO-X is the first federally approved product in Mexico and was featured in the October 24 version of Newsweek.

In addition to this, the story features the legal status of the cannabis industry in Mexico, the growing market in California and the story of a little girl suffering from epilepsy and how RSHO-X was able to help her. Moreover, the article also features details of MJNA’s growing presence in the Latin American market and how quickly HempMeds is gaining popularity in the country. The CEO of Medical Marijuana, Dr. Stuart Titus, has claimed that the expansion in Latin America is poised to bring substantial economic growth to the company.

Separately, the company announced that HempMeds has opened a new office in Monterey, Mexico, which would be the new headquarters for its Mexican operations. Added to this, the company has also added Carlos Gonzales, as the new COO of HempMeds. Specifically, Mr. Gonzales would focus on improving the sales and distribution of products, from MJNA’s Mexican subsidiary, specially RSHO-X. Dr. Titus commented on the recent developments, stating that the new office provides them with the opportunity to conduct on-ground operations. He further stated that this would help strengthen their relations with the Mexican government, as they continue to educate lawmakers and health officials about the benefits of CBD.

The CEO also welcomed Mr. Gonzales to the management team and expressed confidence in his ability to perform in the Mexican market. It should be noted here that currently RSHO-X has been cleared for the treatment of neuropathic conditions, related to diabetes. Moreover, MJNA believes that its research could possibly lead to the discovery of CBD based treatments for neuro-degenerative and neurological disorders.

Medical Marijuana Inc (OTCMKTS:MJNA) completed the November 23 trading session with a gain of 30.12% in terms of its share value, to reach a close at $0.108 per share.

Categories
Marijuana MMJ

General Cannabis Corp (OTCMKTS:CANN) Appoints New Director To The Board

General Cannabis Corp (OTCMKTS:CANN) has announced that Duncan Levin has been elected to the company’s board of directors. Mr. Levin is currently the managing partner of Tucker Levin, PLLC and is also a former federal prosecutor. Added to this, he is an expert in the legal aspects of anti-money laundering, anti-fraud and internal investigations. However, more recently he has been working as a consultant for businesses facing anti-fraud, regulatory issues and other complex challenges.

Robert Frichtel, the CEO of CANN, stated that the new director’s background and expertise would help elevate the company, to a whole new level of professionalism. He further went on to state that Mr. Levin’s unique perspective on legal matters would help General Cannabis in moving through uncharted territory. Mr. Frichtel also voiced his optimism by stating that the new director could help General Cannabis in becoming a premier consultant in this field.

Commenting on his appointment, Mr. Levin claimed that General Cannabis is destined to become a leader in the industry and it was a delight to join the board at a time of immense growth. He also stated that the cannabis industry was one of the fastest growing industries in the country and with the wide array of support services offered by General Cannabis, it could very well become a leader in the field. Mr. Levin’s appointment comes soon after the company attended the Marijuana Business Conference & Expo, in Las Vegas.

CANN attended the event on November 16-18, where it got the opportunity to meet investors and other business leaders from the industry. It should be noted here that this conference is considered to be one of the premier marijuana conferences of the year. The event was attended by almost the entire management of the company. Moreover, General Cannabis also hosted an after party on November 16, in honor of the legalization of marijuana in several states.

General Cannabis Corp (OTCMKTS:CANN) lost 11.01% of its share value, during the November 22 trading session, to reach a close at $3.07 per share. The stock had a trade volume of 557,331, during the session.

Categories
Business MMJ

Kaya Holdings Inc (OTCMKTS:KAYS) Reports Substantial Growth In Revenues For 3Q2016

Kaya Holdings Inc (OTCMKTS:KAYS) filed its financial results for the 3Q2016, yesterday, recording a gain of 700% in terms of revenue, on a year-over-year basis. The company noted that all of its revenues for the quarter were generated by its cannabis business, rather than other non-cannabis related endeavors. Moreover, the management claimed that it was on track to reach its target of $1 million sales, for the FY2016.

In the accompanying update, the company provided details about the progress of two new Kaya Shack marijuana superstores, being developed by the company. Moreover, Kaya also announced that it has acquired the services of David Kotler, a former prosecutor, with experience in helping companies in their initial phase of medical marijuana licensing. He also has extensive contacts across the marijuana industry, across the nation. Kaya has announced that Mr. Kotler would be responsible for leading the company’s expansion plans, nationwide. Added to this, with the passing of the proposition 64, the company has decided to construct a broad and well rounded executive team, to head out expansion plans in the new and emerging markets.

Kaya Holdings’ CEO, Craig Frank, revealed that the management thought that it was the right time to explore other opportunities, other than their continued expansion in Oregon. He also expressed confidence in the appointment of Mr. Kotler, as the head of national expansion. Commenting on his appointment, Mr. Kotler stated that he believed his job at Kaya was to provide sound guidance on matters relating to licensing and advise connecting where needed.

For its 3Q2016, Kaya recorded revenues of over $263,000 and a gross profit of over $137,000, as compared to a gross loss of $831, in the previous year. However, KAYS also experienced a surge in operating expenses, which increased by approximately three folds, on a year-over-year basis. The majority of this surge was attributable to professional fees. As such, net loss for the 3Q2016 was over $1.12 million, as compared to $1.11 million, in the previous year.

Kaya Holdings Inc (OTCMKTS:KAYS) had a trade volume of 1.09 million and gained 3.7% in terms of its share value, during the November 22 trading session, to reach a close at $0.084 per share.

Pin It on Pinterest